Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NextCOVE: Booster mRNA-1283.815 vs mRNA-1273.815 in Japan
jRCT2031230699Phase 3Completed
- Sponsor
- Moderna Inc
- Start
- Mar 2024
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, single-blind trial of XBB.1.5 vaccine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Moderna Inc. Primary endpoints: Geometric mean ratio (GMR) of Omicron XBB.1.5 neutralizing antibody titers at Day 29, Solicited local and systemic reactogenicity adverse reactions and 2 more. Started Mar 2024; status: completed.
02
Drugs
XBB.1.5 vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031230699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230699.